News Release

Short chain fatty acids: An 'ace in the hole' against SARS-CoV-2 infection

Scientists find that short chain fatty acids can be used to reduce susceptibility to SARS-CoV-2 infection and mortality from COVID-19

Peer-Reviewed Publication

University of Fukui

Administration of SCFAs into the nasal cavity could be a preventative or therapeutic strategy for COVID-19

image: In a recent study, scientists examined the nasal expression of ACE2 and saw that administration of SCFAs had suppressed ACE2 expression even in the presence of viral RNA. The findings suggest that SFCAs have potential therapeutic applications against COVID-19. view more 

Credit: Kanako Yoshida from University of Fukui

Humans are no stranger to coronavirus (CoV) pandemics. Just like SARS-CoV-2 (the virus that causes COVID-19), another member of the coronavirus family--SARS-CoV--caused the severe acute respiratory syndrome (SARS) epidemic across parts of Asia in 2003. But, its spread was contained way faster than COVID-19. So, what makes SARS-CoV-2 so contagious?

Both SARS-CoV and SARS-CoV-2 viruses bear "spike proteins" which get inside our cells by binding to a protein called angiotensin-converting enzyme 2 (ACE2) that is found in our cells. However, the SARS-CoV-2 spike (S) protein has been found to have a higher binding affinity (10 to 20 times that of SARS-CoV) to ACE2, thus establishing a link between the pathogen and the protein.

Interestingly, recent studies have shown that patients with COVID-19 who have rhinosinusitis (i.e., inflammation of the nose) have a low risk of hospitalization. Moreover, the expression of ACE2 was reduced in patients with rhinosinusitis. Coincidentally, another study has shown that short-chain fatty acids (SCFAs), produced by bacteria in the gut have beneficial effects in allergy and viral infections. These separate findings prompted an investigation of the effect that SCFAs in the nasal cavity against SARS-CoV-2 infection by scientists from the University of Fukui, Japan, led by Dr. Tetsuji Takabayashi.

In a new study published in the American Journal of Rhinology & Allergy, the scientists attempted to understand the effect of SCFAs on ACE2 expression in the nasal passage, and the potential impact on COVID-19 infection. "This is the first report that short-chain fatty acids (SCFAs) effectively reduce the ACE2 levels in human airway epithelial cells," remarks Dr. Takabayashi.

To understand the status of ACE2 expression in patients with allergies, the researchers studied the levels of ACE2 in the inner lining of the nose in patients with seasonal allergic rhinitis induced by Japanese cedar pollen (SAR-JCP) and chronic rhinosinusitis (CRS). Using techniques like real time-PCR to quantify the expression of ACE2, the researchers found that there was no increase in ACE2 expression in in patients with SAR-JCP, whereas it was decreased in patients with CRS.

To better understand the effect of SCFAs on ACE2 expression, the researchers cultured nasal epithelial cells and exposed them to either SFCA and double-stranded RNA (similar to the nuclear material found in some viruses and known to enhance ACE2 expression). Upon examining the expression of ACE2, the researchers saw that the SFCAs had suppressed ACE2 expression in the presence of the RNA as well.

These results suggest that SFCAs has potential therapeutic applications against COVID-19. Dr. Takabayashi explains, "The nasal mucosa exhibits the highest ACE2 expression among human organs and hence is a prominent target of original infection. Therefore, the development of strategies to downregulate ACE2 expression in nasal epithelial cells could reduce SARS-CoV-2 transmission and be useful as a novel therapeutic approach."

The team's timely findings will certainly aid in our fight against COVID-19.



Title of original paper: Regulation of the expression of SARS-CoV-2 receptor angiotensin-converting enzyme in nasal mucosa

Journal: American Journal of Rhinology & Allergy


About University of Fukui, Japan

The University of Fukui is a preeminent research institution with robust undergraduate and graduate schools focusing on education, medical and science, engineering, and global and community studies. The university conducts cutting-edge research and strives to nurture human resources capable of contributing to society on the local, national, and global level.


About Senior Assistant Professor Tetsuji Takabayashi

Dr. Tetsuji Takabayashi is Senior Assistant Professor at the Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui. His research interests include airway allergic inflammation, allergic rhinitis, and sinusitis. He has authored numerous papers on these topics.

About Professor Shigeharu Fujieda

Dr. Shigeharu Fujieda is the Dean at the Faculty of Medical Sciences, University of Fukui, Japan. He was once a researcher at the Department of Clinical Immunology and Allergy of the University of California, Los Angeles (UCLA). Since 2002, he was appointed as a Professor at the Division of Otorhinolaryngology and Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui. His main research interests are allergic rhinitis, eosinophilic chronic rhinosinusitis, and cancer biology. He also works on immunotherapy for allergic rhinitis, having published over 100 papers on these topics. His research achievements have been covered by many media outlets.

About Senior Assistant Professor Kanako Yoshida

Dr. Kanako Yoshida is a Senior Assistant Professor at the Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui. Her research interests include airway allergic inflammation.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.